NCT05617326

Brief Summary

Abdominal aortic aneurysm (AAA) is a localized dilatation of a segment of the aorta artery in its abdominal portion. It affects 1.7% of men aged 65 years and older. In the high-risk population (male smokers aged 65-75 years), its prevalence is estimated to be between 2.8 and 9%. Mortality of ruptured AAAs is high (80% of deaths before hospitalization or perioperatively), whereas mortality of scheduled procedures for unruptured AAAs is less than 5%. AAA screening has been shown to significantly reduce the specific mortality rate in the medium and long term. The French National Authority for Health (HAS) recommends targeted screening for AAA by ultrasound at the radiologist. The target population is male smokers or former smokers aged 65 to 75 years, as well as all persons aged 50 to 75 years with a family history of AAA. Despite recommendations, the rate of access to targeted screening appears low. Ultrasound screening for AAA is a rapid, noninvasive, and reproducible test. It relies primarily on the measurement of the maximum diameter of the abdominal aorta in cross-section. It has been demonstrated that the learning of the ultrasound screening procedure for AAA is very fast and that the performance of non-radiologists trained in this procedure alone is similar to that of radiologists. In addition, new ultra-portable ultrasound devices, inexpensive and with validated performances have appeared on the market in the last few years, making it possible to equip general practitioners (GPs). We propose a simplified care pathway for AAA screening, by equipping GPs with an ultra-portable ultrasound scanner and by training them to perform the screening procedure, which will be performed in the office or at the patient's home, during a usual consultation of general medicine. Our hypothesis is that this new organization will allow better access to screening for the target population, at a lower cost, compared to the current screening method recommended by the HAS (referral of the patient to the radiologist).

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
400

participants targeted

Target at P75+ for not_applicable

Timeline
16mo left

Started Oct 2023

Longer than P75 for not_applicable

Geographic Reach
1 country

5 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress66%
Oct 2023Sep 2027

First Submitted

Initial submission to the registry

November 8, 2022

Completed
7 days until next milestone

First Posted

Study publicly available on registry

November 15, 2022

Completed
11 months until next milestone

Study Start

First participant enrolled

October 2, 2023

Completed
3.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2027

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2027

Last Updated

December 17, 2025

Status Verified

December 1, 2025

Enrollment Period

3.9 years

First QC Date

November 8, 2022

Last Update Submit

December 9, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • AAA screening performed at 1 year

    Percentage of included patients (eligible for AAA screening) who actually received AAA screening ultrasound within 1 year of the inclusion visit

    1 year

Study Arms (2)

screening by a GP

EXPERIMENTAL

Each patient in this group will have a screening for AAA performed by a trained general practitioner

Other: AAA screening by a GP

screening by a radiologist (conventional)

OTHER

Each patient in this group will have AAA screening performed by a radiologist

Other: AAA screening by a radiologist

Interventions

General practitioners in the control group will refer their patients to the radiologist for AAA screening.

screening by a radiologist (conventional)

The GPs included in the experimental group will be trained in AAA screening with an ultra-portable ultrasound machine and will keep an ultrasound machine available (Butterfly iQ+ model). Their patients will be able to be screened by the GP in the office or at home. In case of positive screening, the GP will be able to refer the patients to the radiologist for diagnostic confirmation..

screening by a GP

Eligibility Criteria

Age50 Years - 75 Years
Sexmale
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Male
  • In the absence of a family history of AAA: Patient aged 65 to 75 years, chronic current or past smoker, active smoker (defined as having smoked at least one cigarette per day) or former smoker (defined as having quit smoking less than 20 years ago, regardless of the number of cigarettes smoked).
  • If there is a family history of AAA: Patient between 50 and 75 years of age
  • Express consent to participate in the study
  • Affiliated or beneficiary of a social security plan

You may not qualify if:

  • Patient with a legal protection measure
  • Patient with previous AAA screening less than 5 years old
  • Patient unable to understand the study / give informed consent (cognitive impairment, communication impairment)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (5)

Cabinet IPSO Brotteaux

Lyon, 69006, France

RECRUITING

Cabinet IPSO Saint Martin

Paris, 75003, France

RECRUITING

Cabinet IPSO Nation

Paris, 75011, France

RECRUITING

Cabinet IPSO Italie

Paris, 75013, France

RECRUITING

Cabinet IPSO Ourcq

Paris, 75019, France

RECRUITING

MeSH Terms

Conditions

Aortic Aneurysm, Abdominal

Condition Hierarchy (Ancestors)

Aortic AneurysmAneurysmVascular DiseasesCardiovascular DiseasesAortic Diseases

Study Officials

  • Hervé Picard, MD

    Hôpital Fondation A. de Rothschild

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Amélie YAVCHITZ, MD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
HEALTH SERVICES RESEARCH
Intervention Model
PARALLEL
Sponsor Type
NETWORK
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 8, 2022

First Posted

November 15, 2022

Study Start

October 2, 2023

Primary Completion (Estimated)

September 1, 2027

Study Completion (Estimated)

September 1, 2027

Last Updated

December 17, 2025

Record last verified: 2025-12

Locations